IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 9, 2023 and accepted by EDGAR at Nov 9, 2023, 17:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $291.0k | us-gaap:Revenues |
| Revenue | 6 months2023-04-01 to 2023-09-30 | $846.0k | us-gaap:Revenues |
| Cost of revenue | 3 months2023-07-01 to 2023-09-30 | $117.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-04-01 to 2023-09-30 | $417.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-07-01 to 2023-09-30 | $174.0k | us-gaap:GrossProfit |
| Gross profit | 6 months2023-04-01 to 2023-09-30 | $429.0k | us-gaap:GrossProfit |
| Research and development | 3 months2023-07-01 to 2023-09-30 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-04-01 to 2023-09-30 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-07-01 to 2023-09-30 | $1.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-04-01 to 2023-09-30 | $3.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-04-01 to 2023-09-30 | −$4.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-07-01 to 2023-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-04-01 to 2023-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$2.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-04-01 to 2023-09-30 | −$4.5m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2023-04-01 to 2023-09-30 | −$3.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-09-30 | $3.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $6.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $16.5m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $2.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $2.4m | us-gaap:Liabilities |
| Long-term debt | At period end2023-09-30 | $139.0k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2023-09-30 | $3.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2023-09-30 | $14.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001185185-23-001163. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.